Merxin Ltd and Perlen Packaging have announced that they will co-develop inhaled cannabis products based on Perlen’s BLISTair single use dry powder inhaler, with Merxin developing the formulations and marketing the cannabis DPIs.
The BLISTair device is completely manufactured on a blister machine, without any molded parts, creating an inhaler from thermoformed barrier films while enclosing the dry powder formulation.
Merxin has been primarily a generic device company, offering off-the-shelf inhalation devices, including a multidose blister DPI, for generic inhaler development. In September 2018, Merxin announced that it had signed a deal with a European generics company for development of a tiotropium/olodaterol SMI for the treatment of COPD using Merxin’s MRX004 softmist inhaler.
According to the company, its MRX002 clear MDI PET can, which is designed for pMDI formulation development, “is very popular with cannabinoid pMDI formulators in the US,” and others are developing cannabis products based on the company’s blister and capsule-based DPIs.
Merxin Co-Director Philippe Rogueda said, “Inhaled cannabinoid therapies are a growing segment at Merxin, it is a very exciting market with a lot to invent. The BLISTair is one of the most elegant DPI devices on the market, recipient of multiple awards over the last year. I am thrilled to have secured an agreement with Perlen to create formulations for the BLISTair and bring much needed dosed, safe and reliable cannabis therapies to a market waiting for them. Perlen is a natural fit for us: creative, determined and focussed; we are the future.”
Perlen Packaging Business Development Manager Matteo Trisoglio said, “The BLISTair was developed with the intention to be the most attractable and innovative disposable inhaler. Current requests are proving that our intention and the set targets with this device can become real. . . . The suitable indications for CBD and the easiness of inhalation, on a disposable, low cost device is the perfect match.”
